Sermorelin
The original synthetic GHRH analog with FDA approval history as Geref.
Mechanism of Action
Bioregulator compound with targeted biochemical activity.
Evidence Chain
Sermorelin
COMPOUND
1 Research Goal
• Muscle & Tissue Growth
Evidence Strength
1 article sourced
Knowledge Graph
(2 connections)Overview
Sermorelin acetate is a synthetic peptide consisting of the first 29 amino acids of naturally occurring growth hormone-releasing hormone (GHRH). Originally developed and FDA-approved under the brand name Geref for the diagnosis and treatment of growth hormone deficiency in children, Sermorelin represents the original pharmaceutical GHRH analog. Though the original Geref product was discontinued for commercial reasons, Sermorelin remains an important compound in growth hormone axis research and anti-aging medicine.
Mechanism of Action
Sermorelin acts on GHRH receptors in the anterior pituitary gland, stimulating the synthesis and pulsatile release of endogenous growth hormone. Unlike exogenous GH administration, which suppresses natural GH production, Sermorelin preserves the physiological pulsatile pattern of GH secretion and maintains feedback regulation via somatostatin. This preservation of natural regulatory mechanisms is considered a key advantage in research settings. Sermorelin's effects on GH release are amplified when combined with GHRPs (growth hormone releasing peptides) due to complementary pathways.
Research Highlights
Clinical studies have established Sermorelin's efficacy in stimulating GH release and increasing IGF-1 levels in both children and adults with growth hormone deficiency. Research has explored its potential in age-related GH decline, body composition improvement, sleep quality enhancement, and recovery from injury. Studies have demonstrated that Sermorelin preserves the natural circadian rhythm of GH secretion, which may contribute to a more favorable side effect profile compared to exogenous GH. Research has also investigated its use in combination with GHRPs for synergistic GH stimulation.
Dosage & Administration
In clinical practice, Sermorelin was administered via subcutaneous injection at doses of 15-30 mcg/kg body weight, typically once daily at bedtime to mimic natural GH release patterns. Treatment courses varied based on indication and response. For research use only (RUO).
Safety Profile
As an FDA-approved drug (historically), Sermorelin has a well-characterized safety profile. Common side effects include injection site reactions, flushing, headache, and dizziness. Rare effects include hyperactivity and drowsiness. Sermorelin does not suppress natural GH production upon discontinuation. Contraindicated in patients with active malignancy due to GH-stimulating effects. The original FDA approval was withdrawn for commercial, not safety, reasons.
References
Thorner MO, et al. Sermorelin in growth hormone deficiency. J Clin Endocrinol Metab. 1997. Merriam GR, et al. Sermorelin in elderly subjects. J Clin Endocrinol Metab. 1999. FDA Geref prescribing information. All content is for educational and research purposes only.
Related Compounds
Synergy & Compatibility
(5)Computational assessment of bio-regulatory compatibility with compounds sharing research goals. Scores reflect half-life alignment, receptor target overlap, and bioavailability data.
Computational assessment based on available pharmacology data. Does not account for individual variability, dose-dependent effects, or unstudied interactions. For research use only.
Community Observations
(0)Qualitative, self-reported researcher observations. Distinct from peer-reviewed evidence — not medical advice.
No approved observations yet. Sign in to contribute.
For research use only. Not medical advice.